Keith Tapper CFA, an analyst from BMO Capital, maintained the Buy rating on Neurogene (NGNE – Research Report). The associated price target ...
Failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells ...
Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...
The company, which secured $200 million from investors in a private funding deal last week, learned Tuesday of a serious side ...
Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated ...
Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...
Neurogene is proceeding with a scaled-back study of its proposed NGN-401 gene therapy for the rare genetic neurological disorder Rett syndrome after a serious adverse event left a study participant ...
Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter ...
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Neurogene (NGNE – Research Report) and keeping the price target at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback